Login to Your Account



HCV Nuc IDX184 Gets Partial Clinical Hold; Idenix Swoons

By Marie Powers
Staff Writer

Thursday, August 16, 2012
Two weeks after Idenix Pharmaceuticals Inc. regained global development and commercialization rights to its hepatitis C virus (HCV) candidates after the dissolution of its development and commercialization agreement with Novartis AG, the FDA placed IDX184, a nucleotide polymerase inhibitor, on a partial clinical hold.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription